Nearly 20% Americans have chronic back pain, but 5-6% have inflammatory back pain. These numbers were derived from the 2010 National Health and Nutrition Examination Survey that showed the USA prevalence of axial spondyloarthritis to be 1-1.4% and ankylosing spondylitis to be 0.5%.
All News
Researchers at MD Anderson Cancer Center in Houston prospectively studied 107 RA patients with regard to oral medication (DMARDs, steroids) adherence. They report that adherence was low, ranging from 58-71% overall.
The risk of new H zoster infection was studied among nearly 30,000 new biologic starts and compared rates seen with abatacept, adalimumab, rituximab, infliximab, etanercept, tocilizumab, certolizumab or golimumab initiation.
A psoriasis population survey finds psoriasis or psoriatic arthritis in 1.4%-3.3% of North American and European households. Many (27-53%) rated their disease as “severe”.
Drug Safety Bulletin: Drug Shortages
Patients in a large Swedish registry with ankylosing spondylitis (AS) and spondyloarthritis (SpA) who started a TNF inhibitor were followed for comedication use and TNF inhibitor survival.
A retrospective study of the national register in Sweden identified a total of 11,030 cases with an ankylosing spondylitis (AS) diagnosis (as of 2009) were identified in the National Patient Register, giving a point prevalence of 0.18% in 2009. Men had a higher prevalence of ankylo
Patients rate communication as one of the most important factors in choosing and sticking with a physician. The end product in at least 2/3 of visits is the prescription, yet prescription adherence is substandard in half of our patients. The key is communication.
In the mid-1990s, our Rheumatology Division at the University of Texas Southwestern Medical School became involved with an early trial of a brand new TNF inhibitor.
Current Sunshine Act disclosures do not apply to CME certified educational activities for either the participants or the presenters. CMS has debated and waffled on whether companies would be required to report payments to doctors who speak at, or attend, CME seminars.
Randomized clinical trials are needed to show efficacy and safety, and are needed to back up the claims and indications for a particular drug. The issue of treatment choice has become challenging, especially when choosing to start or augment therapy.
An advisory board has recommended osteoarthritis and a host of disorders for inclusion in the Illinois new medical marijuana program.
In the last 12 months, levothyroxine (Synthroid) was the most prescribed drug in the USA with 21.6 million prescriptions. Adalimumab (Humira) had 8.3 billion in sales, followed by etanercept (Enbrel) at nearly $6 billion.
Unused pills and prescriptions pose a significant safety risk in the home and may contribute to dosing errors or inadvertent drug use. The issue has led the DEA to sponsor national drug disposal programs and local municipalities have followed with similar programs. At issue is who shoul
The FDA has released its guidance document on biosimilar development, stating that this represents its current thinking and may not be the final document. The document was published last week and will be instrumental in the development of biosimilar products in this country. In the
A retrospective review of 77 SoJIA patients revealed that 50-70% achieved inactive disease or remission when treated with IL-1 inhibitors (anakinra, canakinumab). Good responses were seen with tocilizumab or abatacept, but only 8% responded to etanercept.
